4 completed, 1 terminated. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Terminated 1 |
Follow Steatorrhea: new trials by email Literature Review of Steatorrhea trials Research Report on Steatorrhea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF) Ultrase® MT12 - Cystic Fibrosis, Pancreatic Insufficiency | Phase 3 | Completed | Forest Laboratories | 49 | 2009-04-01 | 2017-03-16 |
| Creon in HIV Patients With Steatorrhea Creon 25000, Placebo - Steatorrhea | Phase 3 | Terminated | Abbott | 34 | 2009-01-01 | 2011-08-01 |
| A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Pancrease MT 10.5, or MT 21, Placebo for Pancrease MT 10.5 or MT 21 - Exocrine Pancreatic Insufficiency, Steatorrhea | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 40 | 2008-08-01 | 2014-05-09 |
| Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Ultrase® MT20 - Cystic Fibrosis, Pancreatic Insufficiency | Phase 3 | Completed | Forest Laboratories | 9 | 2007-07-01 | 2017-03-16 |
| Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis PANCRECARB® (pancrelipase), Placebo - Cystic Fibrosis, Pancreatic Insufficiency | Phase 3 | Completed | Digestive Care, Inc. | 29 | 2007-01-01 | 2012-02-22 |
Cystic Fibrosis (4) · Exocrine Pancreatic Insufficiency (4) · Abdominal Pain (1) · Malabsorption Syndromes (1)
Digestive System Diseases (5) · Gastrointestinal Diseases (5) · Intestinal Diseases (5) · Metabolic Diseases (5) · Nutritional and Metabolic Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Infant, Newborn, Diseases (4) · Lung Diseases (4) · Malabsorption Syndromes (4) · Pancreatic Diseases (4) · Respiratory Tract Diseases (4) · Neurologic Manifestations (1) · Pain (1) · Pathological Conditions, Signs and Symptoms (1)
MT 21 (1) · Pancrelipase (1)
Forest Laboratories (2) · Abbott (1) · Digestive Care, Inc. (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)
United States (4) · Canada (1) · Romania (1)
Michael W Konstan, MD (1) · Suntje Sander, PhD (1)